GlassScriptPhysician profile
David M Neifeld
NPI 1376554972
$1,117.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $192 · 2021: $14.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $258.76 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.64 | 2019 | |
| Pfizer INC. | $132.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $77.32 | 2019-2021 | |
| Astellas Pharma US INC | $58.49 | 2019 | |
| Glaxosmithkline, LLC. | $56.91 | 2019 | |
| Novo Nordisk INC | $54.04 | 2019 | |
| Amarin Pharma, INC. | $50.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.83 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.47 | 2019 | |
| Lilly USA, LLC | $33.44 | 2019 | |
| Shire North American Group INC | $27.86 | 2019 | |
| Scilex Pharmaceuticals INC. | $27.44 | 2019 | |
| Valeritas, INC. | $27.34 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $19.29 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Neifeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.